Optimizing Small Molecule Drug Discovery explains how organizations can continue to innovate while controlling rising R&D costs. Although advances in screening technologies, target biology, and methodologies have driven a resurgence in small molecule discovery, the process remains expensive and inefficient. Hidden costs come from workflow complexity, workarounds, high failure rates, disconnected systems, and underutilized data. The paper highlights how these challenges compromise productivity and decision-making. It presents the Dotmatics Small Molecule Drug Discovery solution as an integrated approach that connects data, streamlines workflows, and preserves data value. Real-world examples show how improved efficiency and visibility help teams reduce risk, accelerate discovery, and achieve

Join for free to read